Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis.

Wang JN, Diao S, Tang YJ, Hou AJ, Yuan HB, Zheng Y, Zhou YH.

PLoS One. 2013;8(2):e58077. doi: 10.1371/journal.pone.0058077. Epub 2013 Feb 28.

2.

Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials.

De Rosa S, Caiazzo G, Torella D, Indolfi C.

Int J Cardiol. 2013 Sep 30;168(2):1298-305. doi: 10.1016/j.ijcard.2012.12.003. Epub 2012 Dec 27.

PMID:
23273690
3.

Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.

Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G.

Platelets. 2012;23(4):274-81. doi: 10.3109/09537104.2011.619602. Epub 2011 Oct 11.

PMID:
21988317
4.

Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.

De Luca G, Verdoia M, Suryapranata H.

Atherosclerosis. 2012 Jun;222(2):426-33. doi: 10.1016/j.atherosclerosis.2012.02.041. Epub 2012 Mar 7. Review.

PMID:
22483166
5.

Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Piccolo R, Eitel I, Galasso G, Iversen AZ, Gu YL, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Thiele H, Piscione F.

Vascul Pharmacol. 2015 Oct;73:32-7. doi: 10.1016/j.vph.2015.06.001. Epub 2015 Jun 10.

PMID:
26071862
6.

Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

Thiele H, Wöhrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G.

Lancet. 2012 Mar 10;379(9819):923-31. doi: 10.1016/S0140-6736(11)61872-2. Epub 2012 Feb 21.

PMID:
22357109
8.

Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.

Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.

Circulation. 2010 Dec 21;122(25):2709-17. doi: 10.1161/CIRCULATIONAHA.110.002741. Epub 2010 Nov 15.

9.

Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.

Piccolo R, Eitel I, Iversen AZ, Gu YL, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Thiele H, Piscione F.

EuroIntervention. 2014 Jan 22;9(9):1110-20. doi: 10.4244/EIJV9I9A186.

10.
11.

Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.

Lang SH, Manning N, Armstrong N, Misso K, Allen A, Di Nisio M, Kleijnen J.

Curr Med Res Opin. 2012 Mar;28(3):351-70. doi: 10.1185/03007995.2012.657299. Epub 2012 Jan 31.

PMID:
22292469
12.

Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.

Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.

Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.

13.

Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.

Mehilli J, Ndrepepa G, Kastrati A, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Kufner S, Dirschinger J, Berger PB, Schömig A.

Am Heart J. 2007 Jul;154(1):158.e1-7.

PMID:
17584569
14.

Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry.

Iversen AZ, Pedersen SH, Joens C, Mogelvang R, Galatius S, Galloe A, Abildgaard U, Hansen PR, Madsen JK, Jensen JS.

J Invasive Cardiol. 2011 Jan;23(1):21-6.

15.
16.

Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.

Kubica J, Koziński M, Navarese EP, Tantry US, Grześk G, Fabiszak T, Kubica A, Świątkiewicz I, Bliden KP, Gurbel PA.

Cardiol J. 2012;19(3):230-42. Review.

17.

Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.

Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A.

Thromb Res. 2013 Jul;132(1):e36-41. doi: 10.1016/j.thromres.2013.05.029. Epub 2013 Jun 19.

PMID:
23791395
18.
19.

[Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].

Galache Osuna JG, Sánchez-Rubio J, Calvo I, Diarte JA, Lukic A, Placer LJ.

Rev Esp Cardiol. 2006 Jun;59(6):567-74. Spanish.

20.

ClearWayRX system to reduce intracoronary thrombus in patients with acute coronary syndromes according to optical coherence tomography after abciximab intracoronary local infusion trial (COCTAIL): study rationale and design.

Capodanno D, Prati F, Pawlowsky T, Ramazzotti V, Albertucci J, La Manna A, Robert G, Tamburino C.

J Cardiovasc Med (Hagerstown). 2010 Feb;11(2):130-6. doi: 10.2459/JCM.0b013e32832e0ae1.

PMID:
19829141

Supplemental Content

Support Center